Beta-blockers in atrial fibrillation—trying to make sense of unsettling results | EP Europace | Oxford Academic

Markus Meyer, Daniel Lustgarten, Beta-blockers in atrial fibrillation—trying to make sense of unsettling results, EP Europace, Volume 25, Issue 2, February 2023, Pages 260–262, https://doi.org/10.1093/europace/euad010 Conflict of interest: None declared. Markus Meyer, Daniel Lustgarten, Beta-blockers in atrial fibrillation—trying to make sense of unsettling results, EP Europace, Volume 25, Issue 2, February 2023, Pages 260–262, https://doi.org/10.1093/europace/euad010 Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation. Observational studies and secondary analysis suggested that beta-blockers may be superior to other rate-control medications in atrial fibrillatio

Markus Meyer, Daniel Lustgarten, Beta-blockers in atrial fibrillation—trying to make sense of unsettling results, EP Europace, Volume 25, Issue 2, February 2023, Pages 260–262, https://doi.org/10.1093/europace/euad010 Conflict of interest: None declared. Markus Meyer, Daniel Lustgarten, Beta-blockers in atrial fibrillation—trying to make sense of unsettling results, EP Europace, Volume 25, Issue 2, February 2023, Pages 260–262, https://doi.org/10.1093/europace/euad010 Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recomme